NASDAQ:ATER charts & data provided by TradingView

Latest Insights on ATER

david and goliath amazon Amazon’s $1 Trillion Playbook: How to Buy the Next Market Disruptor
by Charles Mizrahi February 6, 2020 American Investor Today, Trading Strategies
Today, Amazon and Netflix are known as industry disruptors. But in their early days, they were considered underdogs going up against giant brick-and-mortar retail chains. Today, Charles Mizrahi uncovers the one secret that underpins “underdogs” such as Netflix and Amazon.
The latest U.S. private payrolls data are in, and the economy is looking stronger than ever! (If you judge things solely on jobs data, that is.) Jobs Wow Wall Street … Disney, Not so Much
by Joseph Hargett February 5, 2020 Great Stuff
Keepin’ the Bulls Happy I live for moments like today, dear reader. The latest U.S. private payrolls data are in, and the economy is looking stronger than ever! (If you judge things solely on jobs data, that is.) Yes, I know I preach a bit of doom and gloom from time to time, but someone […]
If you don’t think the Wuhan coronavirus outbreak will impact the U.S. economy, I’ve got some bad news for you. The Chinese Time Bomb; Tesla Tendies Time
by Joseph Hargett February 4, 2020 Great Stuff
The Ticking Chinese Time Bomb Sorry to ruin your bull market party, but there’s an issue we need to discuss … like, right now. I’m talking about the Wuhan coronavirus and the U.S.-China “phase 1” trade deal. Here’s the thing: More than 20,000 Chinese are infected with the Wuhan virus, with some 427 dead. Tens […]
Billionaire Ken Griffin’s strategy is an example of how to grow wealth fast. It’s how he made his $13 billion fortune. Invest Like a Billionaire With 1 Simple Trick
by Michael Carr February 4, 2020 Investing, Trading Strategies, Winning Investor Daily
Billionaire Ken Griffin’s strategy is an example of how to grow wealth fast. It’s how he made his $13 billion fortune.
abbvie stock Profit From AbbVie’s Struggles Today
by Chad Shoop February 4, 2020 American Investor Today, Stocks
Abbvie’s flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own versions, will Abbvie’s stock crater in the face of tighter competition? I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further in 2020.

Newsletter Sign Up

Sponsored

CS Care Video

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

“Thirteen of my positions are up well over 50% in less than a year since joining your service. Two are in the triple digits with several close behind. My personal money manager, who works for one of the largest banks in the country, is envious of my gains. I never dreamed this was possible. My trips to China to teach English to young Chinese students is now much more affordable. Thank you for your dedication and help.”

- Chris K.

“I'm very Happy with your services. I hope you don't plan to retire any time soon! My retirement portfolio depends on your expert guidance. Keep up the great work! Thanks.”

- Randy

“Loving the 238% gain after I bought your recommendation in Sept. 2019! This week (July 21, 2020) will be my 1 year anniversary with your amazing team … thanks for the life-changing work you all do! Between all your services, 14 triple-digit gains, the greatest at 358%!"

- Matt

Share This